ResearcherBC Cancer AgencyNo recent work listed
Maria Yi Ho
Matched on ORCID iD 0000-0003-3511-3251; OpenAlex author ID A5030586623, A5103829446. Sources: OpenAlex.
Their work
- Papers
- 2 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2017: 2 papers
Papers 2
- Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX. First author DOI 10.1097/coc.0000000000000193↗
- Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospect… Co-author DOI 10.1097/coc.0000000000000205↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Winson Y. Cheung · 2 shared papers, 2017 · strength 0.16
- Paper Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British… DOI 10.1097/coc.0000000000000205↗
- Paper Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine V… DOI 10.1097/coc.0000000000000193↗
- Sharlene Gill · 2 shared papers, 2017 · strength 0.16
- Paper Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British… DOI 10.1097/coc.0000000000000205↗
- Paper Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine V… DOI 10.1097/coc.0000000000000193↗
- Daniel John Renouf · 2 shared papers, 2017 · strength 0.16
- Paper Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British… DOI 10.1097/coc.0000000000000205↗
- Paper Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine V… DOI 10.1097/coc.0000000000000193↗
- Hagen Fritz Kennecke · 1 shared paper, 2017 · strength 0.08
- Renata D’Alpino Peixoto · 1 shared paper, 2017 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.